Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H12O5 |
| Molecular Weight | 164.1567 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)CC=O
InChI
InChIKey=VRYALKFFQXWPIH-PBXRRBTRSA-N
InChI=1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1
DescriptionSources: http://drug.report/2-Deoxy-D-glucose/Curator's Comment: description was created based on several sources, including:
http://www.wikidoc.org/index.php/2-Deoxy-D-glucose
http://www.drugbank.ca/drugs/DB08831
Sources: http://drug.report/2-Deoxy-D-glucose/
Curator's Comment: description was created based on several sources, including:
http://www.wikidoc.org/index.php/2-Deoxy-D-glucose
http://www.drugbank.ca/drugs/DB08831
2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel). Therapeutically, 2-deoxyglucose is an investigational drug that is being studied as an anticancer and antiviral agent. The exact mechanisms of action of 2-deoxyglucose is still being investigated, but it is known that in hypoxic cancer cells, 2-deoxyglucose is a glycolysis inhibitor that prevents ATP production and, ultimately, cell survival. With respect to antiviral therapy, 2-deoxyglucose was shown to be effective against herpes simplex virus by affecting the virus' ability to penetrate cells. As an experimental drug, 2-deoxyglucose was demonstrated to work as an anticonvulsant in temporal lobe epilepsy. In this condition, 2-deoxyglucose represses the expression of certain proteins that are at high levels after a seizure. Although there are several possible therapeutic indications for 2-deoxyglucose, presently there is no approved indication for 2-deoxyglucose as a therapeutic agent.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7108556 | http://www.ncbi.nlm.nih.gov/pubmed/6848656
Curator's Comment: Known to be CNS penetrant in rat. Human data not available.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2096907 Sources: http://www.ncbi.nlm.nih.gov/pubmed/19258070 |
|||
Target ID: cell surface glycoprotein HSV-1 receptor sites Sources: http://www.ncbi.nlm.nih.gov/pubmed/3015018 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
Sources: http://www.neurogenomex.com/research.html |
Primary | Unknown Approved UseUnknown |
||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
449.2 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20687211 |
45 mg/kg single, oral dose: 45 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
2-DEOXYGLUCOSE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1107.7 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20687211 |
45 mg/kg single, oral dose: 45 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
2-DEOXYGLUCOSE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20687211 |
45 mg/kg single, oral dose: 45 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
2-DEOXYGLUCOSE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Lasting glycolytic stress governs susceptibility to urethane-induced lung carcinogenesis in vivo and in vitro. | 2016-01-05 |
|
| Cytotoxic effects of mithramycin DIG-MSK can depend on the rise of autophagy. | 2015-10 |
|
| 2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways. | 2012-12-15 |
|
| Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. | 2012-12 |
|
| Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. | 2011-10-01 |
|
| Deletion of the Mint3/Apba3 gene in mice abrogates macrophage functions and increases resistance to lipopolysaccharide-induced septic shock. | 2011-09-16 |
|
| Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes. | 2011-05 |
|
| 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. | 2011-04 |
|
| Involvement of H-Ras and reactive oxygen species in proinflammatory cytokine-induced matrix metalloproteinase-13 expression in human articular chondrocytes. | 2011-03-15 |
|
| eNOS activation mediated by AMPK after stimulation of endothelial cells with histamine or thrombin is dependent on LKB1. | 2011-02 |
|
| p53 Protects lung cancer cells against metabolic stress. | 2010-12 |
|
| The M3-muscarinic acetylcholine receptor stimulates glucose uptake in L6 skeletal muscle cells by a CaMKK-AMPK-dependent mechanism. | 2010-07 |
|
| Glucosamine-induced endoplasmic reticulum stress affects GLUT4 expression via activating transcription factor 6 in rat and human skeletal muscle cells. | 2010-05 |
|
| Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. | 2010-04 |
|
| Chronic ingestion of 2-deoxy-D-glucose induces cardiac vacuolization and increases mortality in rats. | 2010-03-15 |
|
| Salacia oblonga extract increases glucose transporter 4-mediated glucose uptake in L6 rat myotubes: role of mangiferin. | 2009-10 |
|
| The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. | 2009-08-04 |
|
| 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer. | 2008-12-02 |
|
| Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. | 2008-09-12 |
|
| Adipose tissue-specific PPARgamma deficiency increases resistance to oxidative stress. | 2008-03 |
|
| Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats. | 2007-10-31 |
|
| NR4A orphan nuclear receptors modulate insulin action and the glucose transport system: potential role in insulin resistance. | 2007-10-26 |
|
| Altered subcellular distribution of the Alzheimer's amyloid precursor protein under stress conditions. | 2007-01 |
|
| Contrasting actions of prolonged mitogen-activated protein kinase activation on cell survival. | 2006-06-30 |
|
| Effect of organophosphate pesticide diazinon on expression and activity of intestinal P-glycoprotein. | 2006-03-01 |
|
| Effect of troglitazone on tumor necrosis factor alpha and transforming growth factor beta expression and action in human adipocyte precursor cells in primary culture. | 2006-03 |
|
| Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. | 2005-11-25 |
|
| Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: induction of antiapoptosis, antioxidant, and detoxification genes. | 2005-06 |
|
| Contribution of the PI 3-kinase/Akt survival pathway toward osmotic preconditioning. | 2005-01 |
|
| Impaired gastric secretion and lack of trophic responses to hypergastrinemia in M3 muscarinic receptor knockout mice. | 2003-12 |
|
| Arsenite stimulated glucose transport in 3T3-L1 adipocytes involves both Glut4 translocation and p38 MAPK activity. | 2003-10 |
|
| Effect of glucoprivation on serotonin neurotoxicity induced by substituted amphetamines. | 2002-11 |
|
| Activation of the ERK pathway and atypical protein kinase C isoforms in exercise- and aminoimidazole-4-carboxamide-1-beta-D-riboside (AICAR)-stimulated glucose transport. | 2002-06-28 |
|
| Effects of antimetabolites to glucose and fatty acids on galanin-1 receptor mRNA levels in the hypothalamic paraventricular and supraoptic nuclei. | 1998-12-21 |
|
| Effect of inhibition of glucose and fat metabolism on galanin-R1 receptor mRNA levels in the rat hypothalamic paraventricular and supraoptic nuclei. | 1998-11-16 |
|
| Effects of overexpression of glutamine:fructose-6-phosphate amidotransferase (GFAT) and glucosamine treatment on translocation of GLUT4 in rat adipose cells. | 1997-11-30 |
|
| Nitrogen dioxide-induced expression of a 78 kDa protein in pulmonary artery endothelial cells. | 1996 |
|
| Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: substrate specificities and effects of transport inhibitors. | 1993-03-15 |
|
| Neonatal capsaicin-treatment in mice: effects on pancreatic peptidergic nerves and 2-deoxy-D-glucose-induced insulin and glucagon secretion. | 1992-06-01 |
|
| Trafficking of glucose transporters in 3T3-L1 cells. Inhibition of trafficking by phenylarsine oxide implicates a slow dissociation of transporters from trafficking proteins. | 1992-02-01 |
|
| Evidence that erythroid-type glucose transporter intrinsic activity is modulated by cadmium treatment of mouse 3T3-L1 cells. | 1991-10-15 |
|
| Effects of insulin and phospholipase C in control and denervated rat skeletal muscle. | 1991-02 |
|
| Insulin regulation of hexose transport in mouse 3T3-L1 cells expressing the human HepG2 glucose transporter. | 1990-11-25 |
|
| Parallel increases in noradrenaline reuptake and release into plasma during activation of the sympathetic nervous system in rabbits. | 1990-09 |
|
| Uptake and binding of radiolabelled phenylarsine oxide in 3T3-L1 adipocytes. | 1990-08-01 |
|
| Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. | 1990 |
|
| A further comparison of insulin- and phorbol ester-stimulated glucose transport in adipocytes. | 1989-08 |
|
| Inhibition of cyclic AMP-dependent induction of ornithine aminotransferase by simple carbohydrates in cultured hepatocytes. | 1987-12 |
|
| A preadipocyte clonal line from mouse brown adipose tissue. Short- and long-term responses to insulin and beta-adrenergics. | 1987-01 |
|
| Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes. | 1985-03-10 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23228990
The recommended dose of 2DG in combination with weekly docetaxel is 63 mg/kg/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/19258070
LKB1-null non-small-cell lung carcinoma cell lines showed a significant decrease in cell viability for all doses tested, even at the lowest dose of 2-deoxyglucose (2.5 mmol/L) compared with LKB1-positive cells.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C344
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
15866
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
1733674
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
SUB62474
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
15193
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
205-823-0
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
108223
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
61-58-5
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
ALTERNATIVE | |||
|
DB08831
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
m4175
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000134458
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
9G2MP84A8W
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
9G2MP84A8W
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
84755
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
2-DEOXY-D-GLUCOSE
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
154-17-6
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
DTXSID1037648
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
5484
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | |||
|
C116618
Created by
admin on Mon Mar 31 19:55:16 GMT 2025 , Edited by admin on Mon Mar 31 19:55:16 GMT 2025
|
PRIMARY | NCIT |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)